CytomX Therapeutics, Inc.
CTMXNasdaqCIK 1501989HealthcareFiscal year ends Dec 31
Reports and events: 198 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-05-0916:09 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-019654 |
| 2023-04-2716:16 ET | DEF 14A | Proxy statementPeriod 2023-06-14 | 0001140361-23-020944 |
| 2023-03-2716:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-009999 |
| 2023-03-2716:11 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-009991 |
| 2023-03-2716:06 ET | 10-K/A | Annual report, amendedPeriod 2021-12-31 | 0000950170-23-009984 |
| 2023-03-1015:36 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-23-067531 |
| 2023-02-2407:00 ET | 8-K | 4.02 Non-reliance on financial statements | 0001193125-23-047460 |
| 2023-01-0516:13 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-002398 |
| 2022-11-2220:05 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-22-290176 |
| 2022-11-0816:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-023210 |
| 2022-11-0816:03 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-023190 |
| 2022-09-2316:07 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-250137 |
| 2022-09-1316:11 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-243709 |
| 2022-08-0416:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-014751 |
| 2022-08-0416:07 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-014737 |
| 2022-07-1316:10 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors | 0001193125-22-192874 |
| 2022-07-0616:10 ET | 8-K | 8.01 Other events | 0001193125-22-188577 |
| 2022-06-2116:16 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-177650 |
| 2022-05-0516:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-007835 |
| 2022-05-0516:05 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-007806 |
| 2022-04-2716:20 ET | DEF 14A | Proxy statementPeriod 2022-06-15 | 0001140361-22-016242 |
| 2022-04-1416:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-105580 |
| 2022-03-2316:33 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-082793 |
| 2022-03-0116:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-002526 |
| 2022-03-0116:06 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-002519 |
| 2022-02-1416:16 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-041752 |
| 2022-02-0709:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-029142 |
| 2022-01-1008:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-22-000174 |
| 2021-11-0416:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-21-003067 |
| 2021-11-0416:07 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-003053 |
| 2021-10-0408:46 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-290428 |
| 2021-08-0516:26 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0000950170-21-000946 |
| 2021-08-0516:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-21-000939 |
| 2021-06-2219:17 ET | 8-K | 5.07 Shareholder vote results | 0001193125-21-195380 |
| 2021-05-0616:12 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-024969 |
| 2021-05-0616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-024964 |
| 2021-04-2816:32 ET | DEF 14A | Proxy statementPeriod 2021-06-16 | 0001140361-21-014772 |
| 2021-03-0416:17 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-069514 |
| 2021-02-2416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-008088 |
| 2021-02-2416:07 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-008081 |
| 2021-01-2517:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-016452 |
| 2021-01-1917:09 ET | 8-K | 2.02 Results of operations; 8.01 Other events | 0001193125-21-011589 |
| 2020-12-2216:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-20-324542 |
| 2020-11-0516:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-051317 |
| 2020-11-0516:07 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001564590-20-051302 |
| 2020-10-0616:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-20-264740 |
| 2020-08-0616:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-037749 |
| 2020-08-0616:06 ET | 10-Q | Quarterly reportPeriod 2020-06-30 | 0001564590-20-037722 |
| 2020-06-2316:16 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-20-176532 |
| 2020-05-2917:10 ET | 8-K | 8.01 Other events | 0001193125-20-155943 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.